Advertisement
News
Subscribe to MDT Magazine News

Patient dies in Biogen MS drug trial

October 19, 2010 11:32 am | by Mass High Tech: The Journal of New England Technology | Comments

In a Phase 2 clinical trial, Biogen Idec and Roche reported their multiple sclerosis treatment, ocrelizumab, showed signs of reducing the disease indications – but they also reported that one patient died during the testing.

TOPICS:

Patient Experience Research Grants Awarded

October 19, 2010 11:31 am | by Bio-Medicine.Org | Comments

DALLAS, Oct. 19 /- As part of its commitment to supporting efforts to improve the patient experience in healthcare, The Beryl Institute has awarded $1,000 grants to ten health care organizations that are exploring effective methods for addressing patient experience issues. (Logo:...

TOPICS:

Professional sports persons should drink more water

October 19, 2010 10:35 am | by EurekAlert | Comments

(FECYT - Spanish Foundation for Science and Technology) Top sports persons must always perform to their maximum capacity, making them the most vulnerable to the effects of dehydration. Now, a new study conducted by researchers from the Universidad de Castilla la Mancha reveals that...

TOPICS:
Advertisement

Cubist makes $250M notes offer

October 19, 2010 10:34 am | by Mass High Tech: The Journal of New England Technology | Comments

Cubist Pharmaceuticals Inc. has announced it will offer up to $250 million aggregate principal amount of its convertible senior notes due 2017.

Healthcare IT firm Carrot Medical raises $1M

October 19, 2010 10:34 am | by Mass High Tech: The Journal of New England Technology | Comments

Carrot Medical LLC, a Boston-based company develops communications systems in healthcare, has raised $1.1 million in an equity offering.

BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors

October 19, 2010 10:33 am | by Bio-Medicine.Org | Comments

SEOUL, South Korea, Oct. 19 /- BioMolecular Therapeutics, Inc. (BMT, Inc.), a new Seoul-based RNAi therapeutics company with a proprietary technology designed to reduce significantly deleterious side effects triggered by conventional siRNA, announced that it has launched its global...

TOPICS:

LifePort Inc. Signs Two Agreements Launching Company Into Mission-Specific Seating

October 19, 2010 10:33 am | by Bio-Medicine.Org | Comments

ATLANTA, Oct. 19 /- NBAA Trade Show -- LifePort Inc. today announced the signing of two agreements that launch the company into customized mission-specific seating. LifePort is a Sikorsky Aerospace Services (SAS) company – the aftermarket division of Sikorsky Aircraft Corp., a...

TOPICS:

Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium

October 19, 2010 10:33 am | by Bio-Medicine.Org | Comments

COLUMBIA, Md., Oct. 19 /- Celsion Corporation (Nasdaq: CLSN ) announced today that two abstracts on the ThermoDox® High Intensity Focused Ultrasound (HIFU) development program have been delivered via oral presentation at the MR-guided Focused Ultrasound 2010 2nd International...

TOPICS:
Advertisement

GTC Biotherapeutics gets $17M offer to go private

October 19, 2010 9:33 am | by Mass High Tech: The Journal of New England Technology | Comments

GTC Biotherapeutics Inc., a Framingham biotechnology firm that has seen its operational funds dwindle and several employees laid off earlier this year, has received a $17 million offer from French strategic partner LFB Biotechnologies to take GTC private.

Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease

October 19, 2010 9:32 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Oct. 19 /- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic...

TOPICS:

Inspiration Biopharmaceuticals' OBI-1 Receives Orphan Drug Designation in Europe

October 19, 2010 9:32 am | by Bio-Medicine.Org | Comments

LAGUNA NIGUEL, Calif., Oct. 19 /- Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia.  Expected to enter pivotal clinical trials before the end of this year, OBI-1 is...

TOPICS:

TYRX AIGISRx antibacterial envelope shows low infection rate, high CIED procedure success

October 19, 2010 8:34 am | by EurekAlert | Comments

(Kureczka/Martin Associates) COMMAND study results showed that patients undergoing CIED (cardiac implantable electronic device) implantation with TYRX Inc.'s FDA-cleared AIGISRx Antibacterial Envelope enjoyed a 99.5 percent rate of successful implantation with an overall infection...

TOPICS:

Where Should Companies Innovate? In Their Enterprises.

October 19, 2010 8:32 am | by Bio-Medicine.Org | Comments

CENTER VALLEY, Pa., Oct. 19 /- Olympus Corporation of the Americas ( www.olympusamerica.com ) today released findings from a Harris Interactive survey of Fortune 1000 executives concerning enterprise innovation – defined as the transformative business processes, practices,...

TOPICS:

Sysmex America Announces Amerinet Hematology Contract

October 19, 2010 8:31 am | by Bio-Medicine.Org | Comments

MUNDELEIN, Ill., Oct. 19 /- Sysmex, a global leader in medical diagnostic testing equipment and information systems technology, today announced a three-year, dual source hematology contract agreement with Amerinet. Amerinet members have immediate purchasing/leasing access to Sysmex...

TOPICS:

Opto Circuits to buy Cardiac Science for $64M

October 19, 2010 7:45 am | by The Associated Press | Comments

Heart diagnostics company Cardiac Science Corp. said Tuesday it is being bought by Opto Circuits Ltd. for about $64 million cash in a tender offer.The company said Opto Circuits, based in India, is paying $2.30 per share, marking a 10 percent premium to Cardiac Sciences closing price of $2.10...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading